Motor neuropathy due to docetaxel and paclitaxel

Neurology

Volumn 47, Issue 1, 1996, Pages 115-118

  Freilich, Ronnie J ^a   Balmaceda, Casilda ^a   Seidman, Andrew D ^a   Rubin, Michael ^b   DeAngelis, Lisa M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; DEPOLYMERIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MICROTUBULE; MOTOR NEUROPATHY; MUSCLE WEAKNESS; OVARY CANCER; PRIORITY JOURNAL; SENSORY NEUROPATHY;

EID: 0030037366     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.1.115     Document Type: Article

References (25)

1. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-279.
2. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-1805.
3. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merabarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993;85:388-394.
4. Forastiere AA, Neuberg D, Taylor SG, De Conti R, Adams G. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group trial. Monogr Natl Cancer Inst 1993;15:181-184.
5. Murphy WK, Fosella FV, Winn RJ, et al. Phase II study of Taxol (NSC 125973) in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-388.
6. Reichman BS, Seidman AD, Crown JP, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993;11:1943-1951.
7. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel (Taxotere) in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994;12:1232-1237.
8. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-2308.
9. Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 1984;25:83-125.
10. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993;19:351-386.
11. Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 1993;11:2010-2020.
12. Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994;12:241-248.
13. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of Taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987;5:1232-1239.
14. Sarosy G, Reed E. Taxol dose intensification and its clinical implications. J Natl Med Assoc 1993;85:427-431.
15. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994;35:304-311.
16. Lipton RB, Apfel SC, Dutcher JP, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989;39:368-373.
17. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 1993;53:523-527.
18. Burris H, Irvin R, Kuhn J, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11:950-958.
19. Extra JM, Rousseau F, Bourhis J, Dieras V, Marty M. Phase I trial of Taxotere (RP 56976, NSC 628503) [abstract]. Proc Am Assoc Cancer Res 1991;32:205.
20. New PZ, Jackson CF, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996;46:108-111.
21. Trudeau ME, Eisenhauer E, Lofters W, et al. Phase II study of taxotere as first line chemotherapy for metastatic breast cancer (MBC). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study [abstract]. Proc Am Soc Clin Oncol 1993;12:64.
22. Balmaceda C, Forsyth P, Seidman AD, Francis P, DeAngelis LM. Peripheral neuropathy in patients receiving Taxotere chemotherapy [abstract]. Ann Neurol 1993;34:313.
23. Hilkens PHE, Verweij J, Stoter G, Vecht CJ, van Putten WLJ, van den Bent MJ. Peripheral neurotoxicity induced by docetaxel. Neurology 1996;46:104-108.
24. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of Taxol. Cancer Res 1987;47:2486-2493.
25. Shahenk Z, Barohn RJ, New PZ, Mendell JR. Taxol neuropathy: electrodiagnostic and sural nerve findings. Arch Neurol 1994;51:726-729.